MapLight presses the pause button; ADC Therapeutics considers what to do with Zynlonta

⏸️ MapLight Therapeutics pauses preclinical and discovery work: The biotech said it will instead focus its resources on advancing its lead candidate, ML-007C-MA, for schizophrenia and Alzheimer’s disease psychosis. MapLight also ...